39143-25-4

Usage

Uses

Since the provided materials do not specify the uses of 4-Amino-1-Benzyl-Piperidine-4-Carboxylic Acid, it is not possible to list its applications as done for Gallotannin. However, given that it is a compound of interest in synthetic chemistry, it may have potential applications in various industries once its properties and effects are better understood. Further research would be necessary to determine its specific uses and benefits.

InChI:InChI=1/C13H18N2O2/c14-13(12(16)17)6-8-15(9-7-13)10-11-4-2-1-3-5-11/h1-5H,6-10,14H2,(H,16,17)

Upstream product

• 28936-94-9 8-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1026596-92-8 di-tert-butyl 8-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-1,3-dicarboxylate 

Downstream Products

• 57611-55-9 4-amino-1-benzyl-4-ethoxycarbonylpiperidine 
• 166180-89-8 1-benzyl-4-ethoxycarbonyl-4-(2-oxopiperidino)piperidine 
• 166180-88-7 1-benzyl-4-(5-chlorovaleramido)-4-ethoxycarbonylpiperidine 
• 166181-27-7 1-benzyloxycarbonyl-4-methylaminocarbonyl-4-(2-oxopiperidino)piperidine 
• 166180-94-5 1-benzyloxycarbonyl-4-carboxy-4-(2-oxopiperidino)piperidine 
• 166180-93-4 1-Benzyloxycarbonyl-4-(ethoxycarbonyl)-4-(2-oxopiperidino)-piperidine 
• 951217-68-8 C₁₃H₁₆N₄O₂ 
• 945892-89-7 8-benzyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one 
• 945947-99-9 3-oxa-1,8-diazaspiro[4.5]decan-2-one 
• 294180-37-3 1-benzyl-4-[(tert-butyloxycarbonyl)amino]-4-(methoxycarbonyl)piperidine 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).

Opioid receptor agonists and application thereof

The invention discloses compounds and salts thereof that can be used as opioid receptor ligands, a preparation method of the compounds, compositions containing the compounds, and a use of the compounds as [mu] opioid receptor agonists; the compounds are used for treatment of [mu] opioid receptor-mediated related diseases, such as pains and pain-related disorders.

1,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to 1,9-diazaspiro undecane compounds having this pharmacological activity, to processes of

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

Design, synthesis, and SAR of tachykinin antagonists: Modulation of balance in NK1/NK2 receptor antagonist activity

Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

Substituted heterocycles

Compounds of formula I STR1 wherein Q1, Q2, Q3, Q4 and Q5 have any of the meanings given in the specification, their N-oxides, and their pharmacuetically acceptable salts are nonpeptide antagonists NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Piperidine derivatives useful as neurokinin antagonists

Compounds of formula I STR1 wherein Q1, Q2, Q3, and Q4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Cyclic amide derivatives for treating asthma

Compounds of formula I STR1 wherein Q1, Q2, Q3, and Q4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.